Affiliation:
1. Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou Municipal Hospital
2. Shangyou Hospital of Tradition Chinese Medicine
3. Tongji University School of Medicine
Abstract
Abstract
Adenosine N1 methylation (m1A) of RNA, a type of post-transcriptional modification, has been shown to play a significant role in the progression of cancer. The objective of the current research was to analyze the genetic alteration and prognostic significance of m1A regulators in kidney renal clear cell carcinoma (KIRC). Genomic and clinicopathological characteristics were obtained from 558 KIRC patients in the Cancer Genome Atlas (TCGA) and Gene Omnibus Expression (GEO) databases. Alterations in the gene expression of ten m1A-regulators were analyzed and survival analysis was performed using the Cox regression method. We also identified three clusters of patients based on their distinct m1A alteration patterns, using integrated analysis of the ten m1A-related regulators, which were significantly related to overall survival (OS), disease free survival (DFS) and tumor microenvironment (TME) immune cell infiltration cells in KIRC. Our findings showed that m1A alteration patterns have critical roles in determining TME complexity and its immune cell composition. Furthermore, different m1A expression patterns were significantly associated with DFS and OS rates in KIRC patients. In conclusion, the identified m1A RNA modification patterns offer a potentially effective way to classify KIRC patients based on their TME immune cell infiltration, enabling the development of more personalized and successful treatment strategies for these patients.
Publisher
Research Square Platform LLC
Reference39 articles.
1. Kidney cancer: the next decade;Turajlic S;Journal of Experimental Medicine,2018
2. Epidemiology and clinicopathological profile of renal cell carcinoma: a review from tertiary care referral centre;Pallagani L;Journal of Kidney Cancer and VHL,2021
3. Review of adjuvant therapies in renal cell carcinoma: evidence to date;Tacconi EM;OncoTargets and therapy,2020
4. Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, et al., editors. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urologic Oncology: Seminars and Original Investigations; 2016: Elsevier.
5. Gender specific mutation incidence and survival associations in clear cell renal cell carcinoma (CCRCC);Ricketts CJ;PloS one,2015